QUCY
Mainz Biomed N.V.
NASDAQ: QUCY · HEALTHCARE · DIAGNOSTICS & RESEARCH
$0.43
-6.65% today
Updated 2026-04-30
Market cap
$6.28M
P/E ratio
—
P/S ratio
11.69x
EPS (TTM)
$-2.70
Dividend yield
—
52W range
$0 – $1
Volume
0.8M
Mainz Biomed N.V. (QUCY) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $577348.00 | $529877.00 | $895479.00 | $893991.00 | $537080.00 |
| Revenue growth (YoY) | — | -8.2% | +69.0% | -0.2% | -39.9% |
| Cost of revenue | $399726.00 | $347726.00 | $385820.00 | $319108.00 | $147288.00 |
| Gross profit | $177622.00 | $182151.00 | $509659.00 | $574883.00 | $389792.00 |
| Gross margin | 30.8% | 34.4% | 56.9% | 64.3% | 72.6% |
| R&D | $481934.00 | $5.02M | $9.59M | $5.84M | $4.96M |
| SG&A | $8.76M | $16.43M | $13.42M | $8.08M | $8.88M |
| Operating income | $-9.72M | $-26.44M | $-26.64M | $-18.70M | $-12.97M |
| Operating margin | -1684.4% | -4990.6% | -2975.5% | -2091.2% | -2414.0% |
| EBITDA | $-11.28M | $-25.72M | $-24.87M | $-19.56M | — |
| EBITDA margin | -1953.9% | -4853.6% | -2777.3% | -2187.8% | 0.0% |
| EBIT | $-11.35M | $-26.10M | $-25.74M | $-20.58M | — |
| Interest expense | $339171.00 | $289324.00 | $559581.00 | $1.08M | $373458.00 |
| Income tax | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-11.69M | $-26.39M | $-26.30M | $-21.65M | $-16.21M |
| Net income growth (YoY) | — | -125.7% | +0.3% | +17.7% | +25.1% |
| Profit margin | -2024.8% | -4979.9% | -2936.5% | -2421.8% | -3018.3% |